Carvedilol
Product Images NDC 70518-3640

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Carvedilol (NDC 70518-3640). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm2 (Carvedilol 3.125mg 70518 3640 01)

Carvedilol 3.125 mg tablet single unit packaging label by RemedyRepack Inc. The label includes the NDC number 70518-3640-01 and states the product is Rx only. Manufactured by Aurobindo in India, the label advises storage between 20-25°C and to refer to the package insert for directions.*

FDA Label Image

Remedy_label (Remedy Label)

Label for Carvedilol 3.125 mg tablets, packed 100 per box. The label includes the NDC number 70518-3640-00, manufacturer Aurobindo from India, and repackaging by RemedyRepack Inc. It advises storage conditions and keeping medication out of children's reach.*

FDA Label Image

Figure 1. Survival Analysis For Copernicus (intent-to-treat) (Carvedilol Fig1)

A survival analysis line graph for COPERNICUS (Intent-to-Treat) depicting mortality percentage over 21 months. Two curves compare mortality rates: one for placebo and one for Carvedilol, showing lower mortality with Carvedilol throughout the period. The graph includes a statistical significance value of P = 0.004.*

FDA Label Image

Figure 2. Effects On Mortality For Subgroups In Copernicus (Carvedilol Fig2)

A forest plot chart showing the effects on mortality for various subgroups in the COPERNICUS study. The plot includes hazard ratios with confidence intervals for subgroups such as men, women, different age groups, races, diabetic status, ischemic condition, heart rate categories, systolic blood pressure levels, spironolactone use, and all patients combined, plotted against a hazard ratio scale ranging from 0.0 to 2.0.*

FDA Label Image

Figure 3. Survival Analysis For Capricorn (intent-to-treat) (Carvedilol Fig3)

A survival analysis line graph for the CAPRICORN study, comparing mortality percentage over 24 months between two groups: Placebo and Carvedilol. The x-axis represents months, ranging from 0 to 24, and the y-axis shows percent mortality, ranging from 0 to 30%. The graph indicates lower mortality in the Carvedilol group compared to Placebo with a P-value of 0.03.*

FDA Label Image

Figure 4. Effects On Mortality For Subgroups In Capricorn (Carvedilol Fig4)

A forest plot titled 'Effects on Mortality for Subgroups in CAPRICORN' showing hazard ratios for various patient subgroups. It compares mortality risk in categories such as age, gender, timing post-MI, prior beta-blocker use, Killip class, thrombolytic therapy, PTCA for MI, history of CHF, use of diuretics, presence of angina, hypertension, diabetes, heart rate, and systolic blood pressure. Hazard ratios with confidence intervals are shown relative to 1.0 on the x-axis.*

FDA Label Image

Chemical Structure (Carvedilol Str)

Chemical structure diagram of Carvedilol, showing its molecular framework with bicyclic rings and side chains, including hydroxyl and methoxy functional groups, consistent with the active ingredient Carvedilol.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.